The effect of gender and age on growth hormone replacement in growth hormone-deficient patients

Hormone and Metabolic Research

Volumn 36, Issue 4, 2004, Pages 247-253

  Hubina, E ^a   Kovacs L ^a   Szabolcs, I ^a   Szucs N ^b   Toth M ^b   Racz K ^b   Czirjak S ^c   Gorombey Z ^a   Goth M I ^a  

^a NATIONAL MEDICAL CENTER   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c NATIONAL INSTITUTE OF NEUROSURGERY   (Hungary)

Author keywords

Age difference; Body composition; Bone density; Carbohydrate metabolism; Gender difference; Growth hormone replacement

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; SOMATOMEDIN C;

ADULT; AGE; AGED; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE MINERAL; CARBOHYDRATE METABOLISM; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SKINFOLD THICKNESS;

ADULT; AGE FACTORS; AGED; BODY COMPOSITION; BONE DENSITY; DIETARY CARBOHYDRATES; ENERGY METABOLISM; FEMALE; GROWTH DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; SEX FACTORS;

EID: 2442543354     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-814458     Document Type: Article

References (43)

1. Veldhuis JD. Gender differences in secretory activity of the human somatropic (growth hormone) axis. Eur J Endocrinol 1996; 134: 287-295
2. Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 2000; 85: 1121-1125
3. Farhy LS, Straume M, Johnson ML, Kovatchev B, Veldhuis JD. Unequal autonegative feedback by GH models the sexual dimorphism in GH secretory dynamics. Am J Physiol Regul Integr Comp Physiol 2002; 282:R753-764
4. Juul A, Pedersen SA, Sorensen S, Winkler K, Jorgensen JOL, Christiansen JS, Skakkebaek NE. Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol 1994; 131: 41-49
5. Nystrom PH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, Arnqvist HJ. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol 1997; 136: 165-172
6. Span JPT, Pieters GF, Sweep CG, Swinkels LM, Smals AG. Plasma IGF-I is a useful marker of growth hormone deficiency in adults. J Endocrinol Invest 1999; 22: 446-450
7. Hobbs CJ, Plymate SR, Rosen CJ, Adler RA. Testosterone administration increases insulin-like growth factor-I levels in normal men. J Clin Endocrinol Metab 1993; 77: 776-779
8. Block GJ, de Boer H, Gooren LJG, van der Veen EA. Growth hormone substitution in adult growth hormone deficient men augments androgen effects on the skin. Clin Endocrinol 1997; 47: 29-36
9. Faria ACS, Berkenstein LW, Booth RAJr, Vaccaro VA, Asplin CM, Veldhuis JD, Thorner MO, Evans WS. Pulsatile growth hormone release in normal women during the menstrual cycle. Clin Endocrinol 1992; 35: 591-596
10. Burman P, Johannsson AG, Siegbahn A, Vessby B, Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 1997; 82: 550-555
11. Malmlöf K, Johansen T. Growth hormone-mediated breakdown of body fat: insulin and leptin responses to GH are modulated by diet composition and caloric intake in old rats. Horm Metab Res 2003; 35: 236-242
12. Drake WM, Rodriguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol 2001; 54: 525-532
13. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998; 83: 3913-3919
14. Ekman B, Lindström T, Nyström F, Olsson AG, Toss G, Arnqvist HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentration of IGF-I in hypopituitary adults. Eur J Endocrinol 2002; 147: 49-57
15. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. J Clin Endocrinol Metab 1999; 84: 3929-3935
16. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rosen T, Thoren M, Bengtsson BA. The individual responsiveness to growth hormone (GH) treatment in GH deficient adults is dependent on the level of GH-binding protein, body mass index and gender. J Clin Endocrinol Metab 1996; 81: 1575-1581
17. Span JP, Pieters GF, Sweep FG, Hermus AR, Smals AG. Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J Clin Endocrinol Metab 2001; 86: 4161-4165
18. Ezzat S, Fear S, Gaillard RC, Gayle C, Landy H, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults. J Clin Endocrinol Metab 2002; 87: 2725-2733
19. Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KK, Lombardi G, Luger A, Marek J, Russell-Jones D, Sonksen P, Attanasio AF. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. J Clin Endocrinol Metab 2002; 87: 1974-1979
20. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993; 76: 1344-1348
21. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993; 39: 409-415
22. Rosén T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson BA. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone to growth hormone deficient adults. Endocrinol Metab 1994; 1: 55-66
23. Holmes SJ, Whitehous RW, Swindell IR, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adult onset growth hormone deficiency. Clin Endocrinol 1995; 42: 627-633
24. Amato G, Izzo G, La MontagnaG, Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol 1996; 45: 27-32
25. Finkenstedt G, Gasser RW, Höfle G, Watfah C, Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: result of double-blind placebo-controlled study with open follow-up. EurJ Endocrinol 1997; 136: 282-289
26. Johannsson AG. Gender difference in growth hormone response in adults. J Endocrinol Invest 1999; 22: 58-60
27. Valimaki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol 1999; 140: 545-554
28. Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The ef-fects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002; 17: 1081-1094
29. Salomon F, Umpleby M, Cuneo RS, Sönksen PH. Protein, fat and glucose metabolism during treatment with recombinant human growth hormone in adults with growth hormone deficiency. Short and long term effects. Endocrinol Metab 1997; 4: 121-128
30. Rosenfalc AM, Fisker S, Hilsted J, Dinesen B, Volund A, Jorgensen JO, Christiansen JS, Madsbad S. The effect of the deterioration of insulin sensitivity on cell function in growth hormone deficient adults following 4-month growth hormone replacement therapy. Growth Horm IGF Res 1999; 9: 96-105
31. Rosenfalc AM, Maghsoudi S, Fisker S, Jorgensen JO, Christiansen JS, Hilsted J, Volund A, Madsbad S. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab 2000; 85: 4173-4181
32. Simpson H, Savine R, Sönksen P, the GRSCouncil: Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Cohen P, Hintz R, Ho K, Mullis P, Robinson I, Strasburger C, Tanaka T, Thorner MO. GH replacement therapy for adults: into the new millenium. Growth Horm IGF Res 2002; 12: 1-33
33. Riedl M, Ludvik B, Pacini G, Clodi M, Kotzman H, Wagner O, Kautzky-Willer A, Prager R, Luger A. The increased insulin sensitivity in growth hormone-deficient adults is reduced by growth hormone replacement therapy. Eur J Clin Invest 2000; 30: 771-778
34. Al-Shoumer KA, Gray R, Anyaoku V, Hughes C, Beshyah S, Richmond W, Johnston DG. Effects of four years treatment with biosynthetic human growth hormone on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol 1998; 48: 795-802
35. Gibney J, Wallace JD, Spinks T, Schnorr L, Racinar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russel-Jones D. The effect of 10 years recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 1999; 84: 2596-2602
36. Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P, Wuster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol 1999; 50: 703-713
37. Johannsson AG, Engström BE, Ljunghall S, Karlsson FA, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999; 84: 2002-2007
38. Abrahamsen B, Hangaard J, Horn HC, Hansen TB, Gregersen G, Hansen-Nord M, Vahl N, Junker P, Andersen M, Hagen C. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult-onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 2002; 57: 273-281
39. Bengtsson BA, Thunander M, Mattsson A, Abs R, Feldt-Rasmussen U, Goth M, Monson J, Koltowska-Haggström M, Wilton P. The risk of diabetes mellitus in hypopituitary patients on growth hormone substitution 6th European Congress of Endocrinology, 26-30. April, 2003. Lyon. France. Abstract Book P0239
40. Seminara S, Merello G, Masi S, Filpo A, La CauzaF, D"Onghia G, Martelli E, Loche S. Effect of long-term growth hormone treatment on carbohydrate metabolism in children with growth hormone deficiency. Clin Endocrinol 1998; 49: 125-130
41. Christ ER, Cummings MH, Lumb PJ, Crook MA, Sonksen PH, Russell-Jones DL. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study. Clin Endocrinol 1999; 81: 173-179
42. Florakis D, Hung V, Kaltas G, Coyte D, Jenkins PJ, Chew SL, Grossman AB, Besser GM, Monson JP. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol 2000; 53: 453-459
43. Murray RD, Skillicorn CJ, Howell SJ, Lissett CA, Rahim A, Shalet SM. Dose titration and patients selection increases the efficacy of GH replacement in severely GH deficient adults. Clin Endocrinol 1999; 50: 749-757